Because several Jak2 inhibitors have been developed and under clinical evaluation as therapeutic agents for myeloproliferative neoplasms with only limited success [11], the combined effects of Jak2 inhibitors and DNA-damaging chemotherapeutic agents and the mechanisms involved in possible synergy are warranted to be studied in detail to develop effective therapeutic strategies for these diseases. Here, JAK2 is linked to myeloproliferative neoplasm.